Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003645 · ClinicalTrials.gov registry record · Phase 3
Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence
A Phase 3 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 64
- Enrollment target
NCT00003645: Clinical Trial Phase 3 study, sponsored by M.D. Anderson Cancer Center.
NCT00003645 is a Phase 3 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 64 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003645, a Phase 3 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 64 participants
- Enrollment target
Study Summary
RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone. It is not yet known whether receiving leuprolide and flutamide is more effective than receiving no further therapy. PURPOSE: Randomized phase III trial to determine the effectiveness of hormone therapy in treating patients who have stage I or stage II prostate cancer that is at high risk of recurrence and who have already undergone surgery.
Interventions
- DRUG Leuprolide Acetate
- DRUG Flutamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 1999-06-14 |
| Est. Completion | 2017-03-20 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003645
The ClinicalTrials.gov registry entry for NCT00003645 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Leuprolide Acetate is the first listed.
NCT00003645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003645 about?
NCT00003645 is a clinical study titled "Randomized Trial of Adjuvant Hormonal Therapy in Surgically Treated Prostate Cancer Patients at High Risk for Recurrence". RATIONALE: Testosterone can stimulate the growth of prostate cancer cells. Hormone therapy using leuprolide and flutamide may fight prostate cancer by reducing the production of testosterone. It is not yet known whether receiving leuprolide and flutamide is more effective than receiving no further t...
What is the current status of trial NCT00003645?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 64 participants. The study started on 1999-06-14. Estimated completion is 2017-03-20.
What interventions are being tested in trial NCT00003645?
The interventions under investigation include: Leuprolide Acetate (DRUG), Flutamide (DRUG).
Who is sponsoring clinical trial NCT00003645?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.